Xilio Therapeutics reports Q4 2025 results, extends cash runway to 2027

Go back to Xilio Therapeutics reports Q4 2025 results, extends cash runway to 2027
(NASDAQ: XLO) Delayed: 8.79 --0 (-0%)
Previous Close $8.79    52 Week High
Open $8.79    52 Week Low
Day High $8.79    P/E N/A 
Day Low $8.79    EPS
Volume 235,022